Whats the next step for the Critical Path, now that the Opportunities List has been published?
Well, for us, which is all I can say, the next step is going to have to be that the FDA gets some money to work on these things. The President is asking for $6 million in the next year’s budget, so they’ll have staff to work on these initiatives. That’s a pittance. That’s an embarrassing number, but it’s better than nothing. But the agency has found, and we’ve found scientists within the agency willing to work at night and weekends to help us plan these projects. So we’re going to be looking at other projects. We’ve got a project with their Pharmacogenomics Group on warfarin that we were able to get directed funding into this year’s budget. That will be with the University of Utah to evaluate genomically based dosing of warfarin compared to conventional warfarin dosing. Has that already started? It’s already underway. They’ve already enrolled 20 patients into the trial. They’re doing it with their own funding, but it’ll be part of our collaborative project with the FDA. That’s with Jef
